With a revenue increase of 31.74% in the second quarter 2026, year on year to cumulative value of $831 million, Corcept Therapeutics Inc's revenue per employee grew on a trailing twelve months basis to $ 1,138,100, this is below the company average. Within the Healthcare sector Employees of 78 other companies have achieved higher revenue per employee. While Corcept Therapeutics Inc's total ranking has deteriorated compared to the previous quarter from 237 to 817. Corcept Therapeutics Inc has 730 employees.
Corcept Therapeutics: Navigating Financial Fortitude and Pioneering Oncologic Innovations In a landscape marked by relentless dynamism and evolving healthcare paradigms, Corcept Therapeutics Incorporated (NASDAQ: CORT), headquartered in Redwood City, California, has intriguingly underscored its resolve to traverse the ever-challenging terrains of endocrinologic, oncologic, metabolic, and neurologic disorders. With precision in strategic foresight and an unswerving commitment to therapeutic advancement, Corcept continues to etch its indelible imprint on the healthcare sector through its innovative modulation of cortisol effects. Financial Performance Amidst an Evolving Healthcare Sector The third quarter of 2025 manifested as an emblem of steadfast growth for Corcept Therapeutics hypercortisolism division, evincing the organisation s potent combination of scientific innovation and commercial acumen. The company, placed in the crucible of global healthcare challenges, reported an impressive milestone, with the revenue per employee ascending to an enviable $2,034,318 on a trailing twelve-month basis. This financial feat is complimented by an 18.7% augmentation in revenue, year-on-year, culminating in an unprecedented $716 million establishing a new pinnacle in the company’s storied trajectory.
Corcept Therapeutics Advances Oncology Portfolio with Marketing Authorization Application for Relacorilant in Platinum-Resistant Ovarian Cancer In a significant stride for oncological therapeutics, Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational drug, relacorilant. This submission aims to establish relacorilant as a treatment option for patients suffering from platinum-resistant ovarian cancer, a condition associated with limited therapeutic alternatives and poor prognosis.Corcept Therapeutics specializes in the discovery and development of medications targeting severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol s effects an approach that has propelled the company’s research and clinical development domains. The focused submission of the MAA underscores Corcept s commitment to addressing the significant unmet medical needs in the oncology space, specifically for patients who develop resistance to platinum-based chemotherapies.
FDA Accepts Corcept s New Drug Application for Relacorilant to Address Platinum-Resistant Ovarian Cancer In a significant development for the field of oncology and therapeutic treatments, Corcept Therapeutics Incorporated, a company based in Redwood City, California, has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for relacorilant. This announcement marks an important milestone for Corcept, as relacorilant is proposed as a potential treatment for patients suffering from platinum-resistant ovarian cancer a particularly challenging form of cancer due to the difficulty in treatment and high recurrence rates.Corcept Therapeutics, listed on NASDAQ under the ticker CORT, is a commercial-stage company that has built its reputation on discovering and developing medications aimed at modulating the effects of the hormone cortisol to treat a variety of severe disorders. The company s focus spans endocrinologic, oncologic, metabolic, and neurologic conditions, making it a critical player in the domain of innovative drug therapies.
: In a significant advancement in the treatment of platinum-resistant ovarian cancer, Corcept Therapeutics Inc. has reported that the primary endpoint of its phase-3 ROSELLA study evaluating Relacorilant has been achieved. This article provides an overview of the study findings, implications for clinical practice, and considerations for stakeholders in the pharmaceutical industry. Ovarian cancer remains one of the most challenging malignancies to treat, particularly in patients who exhibit resistance to platinum-based chemotherapy. The need for effective treatments in this area has driven extensive research efforts. Corcept Therapeutics Inc. has focused on Relacorilant, a novel compound designed to target and inhibit the action of the glucocorticoid receptor. Recent data from the phase-3 ROSELLA study is promising, indicating potential new pathways for intervention in this difficult-to-treat population.
Corcept Therapeutics Submits New Drug Application Amidst Rising Revenues and Competitive Challenges Corcept Therapeutics Inc. recently announced the submission of a New Drug Application (NDA) for its innovative treatment, Relacorilant, aimed at addressing the needs of patients suffering from hypercortisolism. This milestone could represent a significant advancement in the management of this condition, which is characterized by abnormally high levels of cortisol, often leading to severe health complications.In tandem with this development, Corcept has demonstrated notable financial performance in its recent quarterly reports. The company’s revenue per employee surged to $1,785,668, reflecting an impressive 47.69% increase in revenue during the third quarter of 2024 compared to the same period the previous year. Cumulatively, Corcept s revenue reached a new high of $629 million, underscoring the firm’s growth trajectory and capitalizing on its expertise in managing cortisol-related disorders.
Corcept Therapeutics Incorporated has made significant strides in the development of cortisol modulators with the recent submission of a New Drug Application (NDA) for relacorilant, aimed at treating endogenous hypercortisolism, and the release of promising results from a Phase 2 study evaluating dazucorilant in patients with amyotrophic lateral sclerosis (ALS).Corcept Therapeutics, a commercial-stage biopharmaceutical company, specializes in developing innovative therapies to address severe endocrinologic, oncologic, metabolic, and neurologic disorders by targeting the hormone cortisol. The company s recent initiatives highlight its commitment to addressing critical health concerns associated with cortisol dysregulation.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
